SEHK:401

Stock Analysis Report

Wanjia Group Holdings

Executive Summary

Wanjia Group Holdings Limited, an investment holding company, engages in pharmaceutical wholesale and distribution business in the People’s Republic of China.

Snowflake

Fundamentals

Imperfect balance sheet and overvalued.


Similar Companies

Share Price & News

How has Wanjia Group Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-14.8%

401

4.0%

HK Healthcare

3.3%

HK Market


1 Year Return

-59.4%

401

-23.4%

HK Healthcare

1.6%

HK Market

Return vs Industry: 401 underperformed the Hong Kong Healthcare industry which returned -23.4% over the past year.

Return vs Market: 401 underperformed the Hong Kong Market which returned 1.6% over the past year.


Shareholder returns

401IndustryMarket
7 Day-14.8%4.0%3.3%
30 Day-13.3%0.4%-0.009%
90 Day-34.2%-3.5%-5.1%
1 Year-59.4%-59.4%-21.7%-23.4%5.3%1.6%
3 Year-89.4%-89.4%-32.0%-36.0%16.1%4.4%
5 Year-90.4%-90.4%-27.8%-34.1%20.4%0.3%

Price Volatility Vs. Market

How volatile is Wanjia Group Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Wanjia Group Holdings undervalued compared to its fair value and its price relative to the market?

0.48x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate 401's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate 401's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 401 is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: 401 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate 401's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 401 is good value based on its PB Ratio (0.5x) compared to the HK Healthcare industry average (1.4x).


Next Steps

Future Growth

How is Wanjia Group Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wanjia Group Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Wanjia Group Holdings performed over the past 5 years?

58.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 401 is unprofitable, but has reduced losses over the past 5 years at a rate of 58.4% per year.

Accelerating Growth: Unable to compare 401's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 401 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (5.6%).


Return on Equity

High ROE: 401 has a negative Return on Equity (-43.06%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: 401 is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: 401 is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Wanjia Group Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 401's short term assets (HK$98.5M) exceeds its short term liabilities (HK$91.5M)

Long Term Liabilities: 401 has no long term liabilities


Debt to Equity History and Analysis

Debt Level: 401's debt to equity ratio (44.4%) is considered high

Reducing Debt: 401's debt to equity ratio has increased from 8.4% to 44.4% over the past 5 years.


Balance Sheet

Inventory Level: 401 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 401's debt is covered by short term assets (assets are 1.641810x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 401 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 401 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -72.1% each year


Next Steps

Dividend

What is Wanjia Group Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.3%markettop25%6.3%industryaverage2.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate 401's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 401's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 401's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 401's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 401's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

What is the CEO of Wanjia Group Holdings's salary, the management and board of directors tenure and is there insider trading?

5.0yrs

Average board tenure


CEO

Wanjia Group Holdings has no CEO, or we have no data on them.


Board Age and Tenure

5.0yrs

Average Tenure

51yo

Average Age

Experienced Board: 401's board of directors are considered experienced (5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Michael Yu (54yo)

    Company Secretary

    • Tenure: 0.8yrs
  • Jinshan Chen (51yo)

    Executive Director

    • Tenure: 5yrs
    • Compensation: HK$1.09m
  • Jia Wang (30yo)

    Vice President of Projects Management & Executive Director

    • Tenure: 1.2yrs
    • Compensation: HK$1.24m

Board Members

  • Tiger Wong (52yo)

    Independent & Non-Executive Director

    • Tenure: 6.5yrs
    • Compensation: HK$147.00k
  • Yongping Liu (63yo)

    Independent Non-Executive Director

    • Tenure: 5.7yrs
    • Compensation: HK$147.00k
  • Man Ho (50yo)

    Independent Non-Executive Director

    • Tenure: 1.7yrs
    • Compensation: HK$147.00k
  • Jinshan Chen (51yo)

    Executive Director

    • Tenure: 5yrs
    • Compensation: HK$1.09m
  • Jia Wang (30yo)

    Vice President of Projects Management & Executive Director

    • Tenure: 1.2yrs
    • Compensation: HK$1.24m

Company Information

Wanjia Group Holdings Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Wanjia Group Holdings Limited
  • Ticker: 401
  • Exchange: SEHK
  • Founded: 2004
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: HK$44.818m
  • Shares outstanding: 933.70m
  • Website: https://www.wanjia-gp.com

Number of Employees


Location

  • Wanjia Group Holdings Limited
  • Room 1902
  • 19th Floor
  • North Point
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
401SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDOct 2013

Biography

Wanjia Group Holdings Limited, an investment holding company, engages in pharmaceutical wholesale and distribution business in the People’s Republic of China. It also offers hemodialysis treatment and cons ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 12:51
End of Day Share Price2019/10/17 00:00
Earnings2019/03/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.